Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male or Female ≥18 and ≤70 years old~* History of active ulcerative colitis of at least 3 months duration~* Active UC should be confirmed by colonoscopy or flexible sigmoidoscopy during the screening period within 7 days prior to randomization.~* Moderate to severe ulcerative colitis at time of screening, confirmed by Mayo score ≥6 to 12 and endoscopy subscore of ≥2 despite treatment with immunosuppressants and/or anti-tumor necrosis factors (TNFs):~  * Immunosuppressants: Patient must be on concurrent treatment with or have had an inadequate response to (did not respond to or lost response to) or be intolerant to immunosuppressants such as azathioprine, 6-mercaptopurine, or methotrexate.~ * AND/OR~ * TNF-alpha antagonists: Patient must have had an inadequate response or lost response or be intolerant to TNF-alpha antagonists~* Fecal calprotectin ≥200mg/kg~* Patients on corticosteroids must be on a stable dose ≥2 weeks prior to screening~* Patients on azathioprine, 6- mercaptopurine or methotrexate must be on treatment for at least 12 weeks prior to screening; and on a stable dose ≥4 weeks prior to screening~* Patients on oral 5-aminosalicylates, mesalamine or sulfasalazine must be on a stable dose for ≥4 weeks prior to screening~* Patients naïve to anti-TNF alpha or non-responder (primary or secondary) or intolerant to anti-TNF alpha~* Signed written informed consent~Exclusion criteria:~* Patients with Crohn's Disease~* Diagnosis of indeterminate colitis~* Patients with stool sample positive for ova, parasites, or positive culture for aerobic pathogens including: Aeromonas, Plesiomonas, Shigella, Yersinia, Campylobacter and E. Coli spp. or positive for Clostridium difficile B toxin in stools.~* Patients with prior colectomy or anticipated colectomy during their participation in the study~* Presence of ileal pouch or ostomy~* Fulminant disease or toxic megacolon~* Colonic dysplasia except for adenoma~* Total Parenteral Nutrition~* Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide or tacrolimus within 2 months prior to screening~* Previous exposure to natalizumab (Tysabri®) or vedolizumab~* Antidiarrheals within 2 weeks prior to screening~* Prednisone \>40 mg/day (or equivalent)~* Budesonide \>9 mg/day~* Received intravenous corticosteroids within 2 weeks prior to screening or during screening~* Rectally administered topical 5-aminosalicylate or corticosteroids within 4 weeks prior to screening~* Received therapeutic enema or suppository, other than required for colonoscopy or flexible sigmoidoscopy within 4 weeks prior to screening or during screening~* Antibiotics for ulcerative colitis or gastrointestinal infection within 4 weeks prior to screening~* Patient who has previously participated in any clinical trial of GBR500 / SAR339658~* Patient who has taken other investigational medications within 2 months or 5 half lives, (whichever is longer) prior to screening~* Use of any biologics for the treatment of ulcerative colitis in the previous 8 weeks before screening~* Requirement for concomitant treatment that could bias primary evaluation~* Pregnant or breast-feeding women~* Women of childbearing potential not protected by highly effective contraceptive method of birth control~* Patient with latent or active tuberculosis (TB) defined as:~  * Any signs or symptoms suggestive of active TB upon medical history or clinical examination~ * Patients with a positive QuantiFERON TB Gold Test~ * Chest radiograph within 3 months prior to the inclusion visit consistent with prior tuberculosis infection including, but not limited to, apical scarring, apical fibrosis, or multiple calcified granulomasa. This does not include non-caseating granulomasa~ * Patients with close contact with a person with active tuberculosis~* Patient with a history of listeriosis or tuberculosis (unless it is documented that they were adequately treated)~* Administration of any live (attenuated) vaccine within 3 months prior to the screening Visit (eg, varicella-zoster vaccine, oral polio, rabies)~* Positive Hepatitis B surface antigen (HBsAg) or positive Hepatitis B core antibody (HBcAb); and/or positive Hepatitis C antibody (HCV) at the Screening Visit~* Prior opportunistic infections within 6 months prior to screening or while receiving anti-TNF treatment~* History of a hypersensitivity reaction, other than localized injection site reaction, to any biological molecule~* History or any current signs of demyelinating disease or any neurological disease that can by the opinion of Investigator interfere with study safety assessments including assessment for progressive multifocal leukoencephalopathy~* Patients with bleeding disorders or known platelet dysfunction~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SAR339658 (Type: EXPERIMENTAL): SAR339658 at Weeks 0, 2, 4, and 6
- Placebo (Type: PLACEBO_COMPARATOR): Placebo at Weeks 0, 2, 4, and 6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues